In recent years, the emergence of immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting the programmed cell death-(ligand) 1 (PD-1/PD-L1) pathway, has transformed the treatment landscape and significantly improved the prognosis of ES-SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.